Some substrate drugs also act as ABC transporter reversal agent, hence, we next evaluated the reversal capacity of gedatolisib at low toxic concentrations on ABCB1- or ABCG2-mediated MDR in CRC cells [39]. This evidence concerns the gene ABCB1 and colorectal carcinoma.